Skip to main content
    N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    CONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ

    $2.01
    -0.05 (-2.66%)

    Market Cap: $163.54M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Niagen Bioscience, Inc. (NAGE) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Niagen Bioscience (NAGE) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Niagen Bioscience reported EPS of -$0.01, in line with the -$0.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    42%(15/36)
    Avg Surprise
    +12.13%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.01
    Range-$0.05 - $0.02
    8 analysts
    Revenue Consensus
    $30.52M
    Range$28.91M - $31.90M
    8 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.02
    Range-$0.02 - -$0.02
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.02-200.0%
    60d ago$0.02-200.0%
    30d ago$0.02-200.0%
    7d ago$0.00n/a
    Current-$0.02
    Revenue Consensus
    $31.49M
    Range$29.20M - $33.45M
    4 analysts

    Next Report

    NAGE has an expected report date of Mar 2, 2027.

    NAGE Earnings Call

    The latest NAGE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, NAGE beat 15, missed 13 and matched 8. Revenue for the quarter ended Sep 30, 2026 was $27.19M, down 20.0% from $33.99M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.01-$0.01N/A0.00%In line-120.0%10 up, 1 downNov 4, 2026$27.19M
    Jun 30, 2026$0.01$0.01N/A0.00%In line-75.0%10 up, 0 downAug 4, 2026$29.79M
    Mar 31, 2026$0.02$0.06$0.06 - $0.06-66.67%Miss-60.0%11 up, 0 downMay 6, 2026$31.47M
    Dec 31, 2025$0.03$0.02$0.01 - $0.02+25.45%Beat-69.3%31 up, 0 downMar 4, 2026$33.84M
    Sep 30, 2025$0.05$0.02$0.01 - $0.04+150.00%Beat+150.0%30 up, 0 downNov 4, 2025$33.99M
    Jun 30, 2025$0.04$0.01-$0.01 - $0.03+300.00%Beat+154.8%30 up, 1 downAug 6, 2025$31.12M
    Mar 31, 2025$0.05$0.02N/A+150.00%BeatN/AN/AN/AMay 7, 2025$30.48M
    Dec 31, 2024$0.09$0.02N/A+350.00%Beat+5900.0%N/AN/AMar 4, 2025$29.13M
    Sep 30, 2024$0.02$0.01N/A+100.00%BeatN/AN/AN/AOct 31, 2024$25.58M
    Jun 30, 2024$0.02-$0.01N/A+257.00%BeatN/AN/AN/AAug 7, 2024$22.74M
    Mar 31, 2024-$0.01-$0.01N/A0.00%In lineN/AN/AN/AMay 8, 2024$22.15M
    Dec 31, 2023$0.00-$0.02N/A+106.67%BeatN/AN/AN/AMar 6, 2024$21.20M
    Sep 30, 2023-$0.01-$0.03N/A+66.67%BeatN/AN/AN/ANov 8, 2023$19.50M
    Jun 30, 2023-$0.03-$0.04N/A+25.00%BeatN/AN/AN/AAug 9, 2023$20.32M
    Mar 31, 2023-$0.03-$0.05N/A+40.00%BeatN/AN/AN/AMay 10, 2023$22.56M
    Dec 31, 2022-$0.02-$0.02N/A0.00%In lineN/AN/AN/AMar 8, 2023$21.00M
    Sep 30, 2022-$0.01-$0.06N/A+83.33%BeatN/AN/AN/ANov 2, 2022$17.06M
    Jun 30, 2022-$0.09-$0.09N/A0.00%In lineN/AN/AN/AAug 10, 2022$16.73M
    Mar 31, 2022-$0.11-$0.09N/A-22.22%MissN/AN/AN/AMay 12, 2022$17.26M
    Dec 31, 2021-$0.08-$0.08N/A0.00%In lineN/AN/AN/AMar 9, 2022$17.76M
    Sep 30, 2021-$0.13-$0.09N/A-44.44%MissN/AN/AN/ANov 3, 2021$17.31M
    Jun 30, 2021-$0.08-$0.08N/A0.00%In lineN/AN/AN/AAug 3, 2021$17.70M
    Mar 31, 2021-$0.12-$0.08N/A-50.00%MissN/AN/AN/AMay 6, 2021$14.68M
    Dec 31, 2020-$0.10-$0.10N/A0.00%In lineN/AN/AN/AMar 10, 2021$15.45M
    Sep 30, 2020-$0.07-$0.09N/A+22.22%BeatN/AN/AN/ANov 4, 2020$14.18M
    Jun 30, 2020-$0.06-$0.10N/A+40.00%BeatN/AN/AN/AAug 6, 2020$15.29M
    Mar 31, 2020-$0.10-$0.11N/A+9.09%BeatN/AN/AN/AMay 11, 2020$14.35M
    Dec 31, 2019-$0.15N/AN/AN/AN/AN/AN/AN/AMar 11, 2020$13.09M
    Sep 30, 2019-$0.12-$0.11N/A-9.09%MissN/AN/AN/ANov 12, 2019$12.05M
    Jun 30, 2019-$0.14-$0.13N/A-7.69%MissN/AN/AN/AAug 7, 2019$11.10M
    Mar 31, 2019-$0.15-$0.12N/A-25.00%MissN/AN/AN/AMay 9, 2019$10.05M
    Dec 31, 2018-$0.15N/AN/AN/AN/AN/AN/AN/AMar 31, 2019$9.07M
    Sep 30, 2018-$0.16-$0.12N/A-33.33%MissN/AN/AN/ANov 7, 2018$8.12M
    Jun 30, 2018-$0.15-$0.13N/A-15.38%MissN/AN/AN/AAug 9, 2018$7.80M
    Mar 31, 2018-$0.15-$0.06N/A-150.00%MissN/AN/AN/AMay 10, 2018$6.57M
    Dec 31, 2017-$0.17N/AN/AN/AN/AN/AN/AN/AMar 31, 2018$7.53M
    Sep 30, 2017-$0.07-$0.05N/A-40.00%MissN/AN/AN/ANov 9, 2017$6.08M
    Jun 30, 2017-$0.05$0.04N/A-225.00%MissN/AN/AN/AAug 10, 2017$4.22M
    Mar 31, 2017-$0.05$0.01N/A-600.00%Miss-835.3%N/AN/AMay 11, 2017$3.37M
    Dec 31, 2016-$0.06N/AN/AN/AN/AN/AN/AN/AMar 31, 2017$1.57M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.17, up 44.9% from the year before. It was -$0.08 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.17+44.9%
    Dec 31, 2024$0.12N/A
    Dec 31, 2023-$0.07N/A
    Dec 31, 2022-$0.23N/A
    Dec 31, 2021-$0.41N/A
    Dec 31, 2020-$0.33N/A
    Dec 31, 2019-$0.56N/A
    Dec 31, 2018-$0.61N/A
    Dec 31, 2017-$0.34N/A
    Dec 31, 2016-$0.08N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,40911
    2026Q1Mar 31, 20265,02110
    2025Q4Dec 31, 20255,5539
    2025Q3Sep 30, 20254,4298
    2025Q1Mar 31, 20255,94911
    2024Q4Dec 31, 20246,56012
    2024Q3Sep 30, 20245,31810

    2026Q3 Earnings Call

    Opening remarks

    Kendall Knysch Senior Director, Publicity and Public Relations Good afternoon, and welcome to Niagen Bioscience, Inc.'s Third Quarter 2026 Conference Call. Joining me today are our Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Dr. Shao will join for the Q&A. Before we begin, I'd like to remind everyone that today's call may include forward-looking statements. These statements relate to, among other things, our relationships with major customers, general economic conditions, the market and size of the vitamin, mineral and dietary supplement market and the intravenous market, our research and development activities, expansion into new markets, business development opportunities and our expected financial and operating performance. These statements are based on our current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to our most recent Form 10-Q and other filings with the SEC. We undertake no obligation to update these statements, except as required by law. In addition, we may reference certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures can be found in today's earnings release and presentation, both available in the Investor Relations section of our website. With that, it is now my pleasure to turn the call over to our Chief Executive Officer, Rob Fried.

    Robert Fried CEO Thank you, Kendall, and good afternoon, everyone. Thank you for joining us on today's investor call. We had a productive third quarter and are laying the foundation for growth with progress across all four pillars of Niagen's NAD platform: Tru Niagen, Niagen Ingredients, Niagen Plus and NAD Pharmaceuticals. Each business is well positioned for significant growth in 2027, with 2026, as we have said before, focused mainly on investing and preparing for that expansion. While the market is experiencing changing dynamics, our core business remains resilient. Low-cost and low-quality products claiming to elevate NAD continue to enter the market. However, our website revenues grew approximately 10% year-over-year, or 17% year-over-year adjusted for Prime Day, which took place in the third quarter in 2025, continuing to demonstrate that there is increasing demand for the most researched, most effective and highest-quality NAD-boosting supplement in the world, Tru Niagen. In the third quarter, we generated approximately $2.6 million in positive operating cash flow and $455,000 of adjusted EBITDA. We ended the quarter with $69.5 million in cash, no debt and $83.3 million in working capital, a $600,000 increase. Our mission is to improve the way people age through the world's leading NAD-boosting technologies.

    Frequently Asked Questions About NAGE

    When is Niagen Bioscience's next earnings date?

    Niagen Bioscience's next earnings report is expected for Mar 2, 2027.

    Did NAGE beat earnings estimates last quarter?

    Niagen Bioscience reported EPS of -$0.01 for the quarter ended Sep 30, 2026, in line with the -$0.01 estimate.

    What EPS do analysts expect from NAGE next quarter?

    The consensus EPS estimate for Niagen Bioscience for the quarter ending Dec 31, 2026 is -$0.01 from 8 analysts, with estimates from -$0.05 to $0.02.

    How often does NAGE beat earnings estimates?

    Niagen Bioscience beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +113.60%.